The HAM-D 7: A Brief Depression Scale to Distinguish Antidepressant Response from Symptomatic Remission

Primary Psychiatry

Volumn 10, Issue 1, 2003, Pages 39-42

  McIntyre, Roger S ^a,b   Fulton, Kari A ^a   Bakish, David ^b   Jordan, J ^c,d   Kennedy, Sidney H ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ARTICLE; DEPRESSION; DISEASE SEVERITY; FEMALE; GENERAL PRACTITIONER; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; PRESCRIPTION; RATING SCALE; REMISSION; SUSTAINED DRUG RELEASE; TORONTO HAMILTON DEPRESSION RATING SCALE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 1842557535     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Canadian Psychiatric Association. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry. 2001;46(suppl 1):77S-90S.
2. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996;276:293-299.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet. 1997;349:1498-1504.
4. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry. 2001;62:523-529.
5. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580-592.
6. Katon W, Korff VM, Lin E, et al. Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry. 1990;12:355-362.
7. Gredon JF. The burden of disease in treatment-resistant depression. J Clin Psychiatry. 2001;62:26-31.
8. Greenberg PE, Stiglin LE, Finlelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:425-426.
9. Nierenberg DW. Teaching clinical pharmacology: a process of 'lifelong learning.' J Clin Pharmacol. 1993;33:311-315.
10. Hamilton M. A rating scale for depression. J Neuro Neurosurg Psychiatry. 1960;23:56-62.
11. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as a predictor of rapid relapse. J Affect Disord. 1998;50:97-108.
12. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55:694-700.
13. Rapaport MH, Judd LL. Minor depressive disorder and subsyndromal depressive symptoms: functional impairment and response to treatment. J Affect Disord. 1997;48:227-232.
14. Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry. 2001;58:221-227.
15. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work Arch Gen Psychiatry. 1992;49:7661-7668.
16. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000;57:375-380.
17. Paykel ES. Remission and residual symptomatology in major depression. Psychopathology. 1998;31:5-14.
18. Ramana R, Paykel ES, Cooper Z, Hayhurst H, Saxty M, Surtees PG. Remission and relapse in major depression: a prospective follow-up study. Psychol Med. 1995;25:1161-1170.
19. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder; remission, recover, relapse and recurrence. Arch Gen Psychiatry. 1991;134:382-389.
20. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994:339-345.
21. Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res. 1993;27:259-273.
22. Hooper CL, Bakish D. An examination of the sensitivity of the six-item Hamilton Rating Scale for Depression in a sample of patients suffering from major depressive disorder. J Psychiatry Neurosci. 2000;25:178-184.
23. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Qualitative rating of depressive states. Acta Psychiatr Scand. 1975;51:161-170.
24. Maier W, Philipp M, Gerken A. Dimensions of the Hamilton Depression Scale. Eur Arch Psychiatry Clin Neurosci. 1985;234:417-422.
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
26. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60:221-225.
27. O'Sullivan RL, Fava M, Agustin C, Baer L, Rosenbaum JF. Sensitivity of the six-item Hamilton Depression Rating Scale. Acta Physiol Scand. 1997;95:379-384.
28. Faires D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res. 2000;34:3-10.
29. Rudolf RL. Goal of antidepressant therapy: response or remission and recovery? J Clin Psychiatry. 1999;60:3-4.